Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma.
Publication
, Journal Article
Shi, W; Lu, T; Xu-Monette, Y; Young, KH
Published in: Chin Clin Oncol
February 2024
Duke Scholars
Published In
Chin Clin Oncol
DOI
EISSN
2304-3873
Publication Date
February 2024
Volume
13
Issue
1
Start / End Page
17
Location
China
Related Subject Headings
- Retrospective Studies
- Prognosis
- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell
- Killer Cells, Natural
- Humans
- Biomarkers, Tumor
- Antibodies, Monoclonal, Humanized
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Shi, W., Lu, T., Xu-Monette, Y., & Young, K. H. (2024). Encouraging prospects with sugemalimab in relapsed or refractory extranodal natural killer/T-cell lymphoma. Chin Clin Oncol, 13(1), 17. https://doi.org/10.21037/cco-23-69
Published In
Chin Clin Oncol
DOI
EISSN
2304-3873
Publication Date
February 2024
Volume
13
Issue
1
Start / End Page
17
Location
China
Related Subject Headings
- Retrospective Studies
- Prognosis
- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell
- Killer Cells, Natural
- Humans
- Biomarkers, Tumor
- Antibodies, Monoclonal, Humanized
- 3211 Oncology and carcinogenesis